KDC-MN-288 – Kodiac biolabs

Our opinion on this compoundEstablished workhorse

46/100

Canonical active thyroid hormone with strong clinical evidence but minimal research frontier value

Look, this is the canonical active thyroid hormone. Liothyronine has been around since before most researchers in this field were born, it binds TR-alpha and TR-beta with roughly 4x the affinity of T4, and the mechanism, genomic transcription of metabolic target genes through nuclear hormone receptor activation, was worked out thoroughly decades ago. That’s not a knock on the compound. It’s a knock on it as a research target in 2026.

What we like about T3 in the context of the library is that its pharmacokinetics make it a genuinely useful probe. The 2.5-day half-life versus T4’s 7-day half-life means you can actually titrate thyroid hormone state in a model organism or cell system with reasonable temporal precision. That has real bench utility for anyone studying metabolic gene regulation, cardiac hypertrophy models, or thyroid receptor biology. Its role as the reference standard for TR assays is legitimate and worth acknowledging.

Here’s the thing though: the interesting thyroid hormone pharmacology right now is happening at selective TR-beta agonists. Resmetirom just got FDA approval for MASH and that story, receptor-subtype selectivity to preserve metabolic benefit while shedding cardiac risk, is where the research conversation is. T3 hits both TR-alpha and TR-beta, which means it carries the full cardiac liability and doesn’t let you cleanly dissect receptor subtype contributions. As a research tool for that question, its nonselective profile is actually a limitation.

The STAR*D T3 augmentation data is real and worth knowing about. Adding T3 25 to 50 mcg to a partially-responding antidepressant did produce a 24.7% remission rate in the augmentation arm of that massive NCI-sponsored trial, which is a meaningful signal. But thats not new territory. The depression augmentation mechanism isn’t well-understood (thyroid hormone’s relationship to neurotransmitter sensitivity, particularly 5-HT1A and beta-adrenergic systems, remains speculative), and nobody is running novel T3 depression trials because the clinical question was largely answered.

We’d put T3 in the library as a reference compound and a functional tool for groups studying thyroid axis biology or receptor pharmacology. For someone building a metabolic research program or doing GH axis work where thyroid hormone status matters as a cofactor, having T3 on hand is just practical. But if you’re looking for something with genuine investigational upside in 2026, the TR-beta selective program is where you’d spend your reading time, not on T3 itself. The evidence is mature. The mechanism is settled. The frontier has moved on.

Novelty: 18
Mechanism promise: 28
In-category differentiation: 38
Evidence quality: 75
Translational signal: 75
Research bench value: 65

Rationale T3 scores well on evidence quality and translational signal as an approved drug with decades of clinical use and STAR*D-validated depression augmentation, but those strengths reflect maturity, not novelty; the compound’s low novelty, well-characterized nuclear receptor mechanism, and limited differentiation relative to emerging TR-beta selective agonists (resmetirom, MGL-3196) drag the overall to the mid-40s despite its reference-standard bench utility.

Active thyroid hormone (T3)

The active thyroid hormone triiodothyronine; faster-acting and more potent than levothyroxine, used in hypothyroidism, depression augmentation, and metabolic research.

Abstract

Liothyronine (3,3′,5-triiodo-L-thyronine, T3; CAS 6893-02-3; molecular formula C15H12I3NO4; molecular weight 650.97) is the active thyroid hormone, marketed as Cytomel for hypothyroidism. The compound binds thyroid hormone receptors (TR-alpha, TR-beta) with approximately 4-fold higher affinity than thyroxine (T4) and produces direct genomic effects on metabolic gene transcription without the conversion delay required for T4. Plasma half-life is 2.5 days, much shorter than T4’s 7-day half-life, producing more variable plasma levels but faster onset and offset. Approved for hypothyroidism (alternative or adjunct to levothyroxine), myxedema coma (intravenous), and as a thyroid suppression test. Off-label use in major depressive disorder augmentation (the STAR*D trial-supported strategy of T3 25 to 50 mcg added to a partially-responding antidepressant), fat loss, and bodybuilding cutting cycles. The cardiac risk is the principal limitation: T3 directly increases myocardial oxygen demand, producing tachycardia, atrial fibrillation, and angina at supratherapeutic doses. Used as the canonical T3 reference compound.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-288Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-288

Liothyronine (T3)

Abstract

Read the full monograph